SCHEMBL121074

SCHEMBL121074

c1ccc2c(c1)Nc1c(ccc3ccccc13)O2

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 11/20 0.55
DHODH Q02127 1/20 0.40
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 2/20 0.38
TAAR1 Q96RJ0 1/20 0.38
HSD17B10 Q99714 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP2A6 P11509 1/20 0.38
TSHR P16473 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GLA P06280 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
SIRT1 Q96EB6 1/20 0.37
HPRT1 P00492 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31191628 1.00 ALOX5 (0.55) ALOX5DHODHCYP1A2CYP2C19TAAR1
SCHEMBL30530994 1.00 ALOX5 (0.55) ALOX5DHODHCYP1A2CYP2C19TAAR1
SCHEMBL28571843 0.98 ALOX5 (0.53) ALOX5DHODHCYP1A2CYP2C19TAAR1
Hydrochloric Acid SCHEMBL31235549 0.98 ALOX5 (0.53) ALOX5DHODHCYP1A2CYP2C19TAAR1
SCHEMBL3421834 0.92 ALOX5 (0.50) ALOX5DHODHCYP1A2CYP2C19TAAR1
Xanthene SCHEMBL4193453 0.89 MAOA (0.49) ALOX5DHODHCYP1A2CYP2C19TAAR1
Nitric Acid SCHEMBL997582 0.88 ALOX5 (0.47) ALOX5ALDH1A1GAAKDM4E
SCHEMBL18162295 0.81 TAAR1 (0.41) CYP1A2CYP2C19TAAR1HSD17B10ALDH1A1
SCHEMBL3894760 0.78 CYP1A2 (0.35) ALOX5CYP1A2CYP2C19TAAR1ALDH1A1
SCHEMBL19971565 0.77 ALOX5 (0.44) ALOX5DHODHALDH1A1TDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1741 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695308-A1 ENGINEERED ANTIBODIES AND USES THEREOF Invitrogen BioServices India Private Limited (IN) 2026-02-18 EP claimed
EP-4687982-A1 METHOD FOR INDUCING TUMOR REGRESSION VeroScience LLC (US) 2026-02-11 EP claimed
WO-2025262706-A1 SITE-SPECIFIC PROTEIN LABELING USING OLIGONUCLEOTIDE TAGS INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED (IN) 2025-12-26 WO claimed
US-20250377301-A1 STABILISED FLUOROPHORES, COMPOSITIONS, METHODS OF PREPARATION, CONJUGATES THEREOF, AND METHODS OF USE FREISTAAT BAYERN LUDWIG MAXIMILIANS UNIV MUENCHEN (DE) 2025-12-11 US claimed
US-12318451-B2 Method for inducing tumor regression VEROSCIENCE LLC (US) 2025-06-03 US claimed
EP-3419542-B1 METHOD AND APPARATUS FOR TIGHTENING SKIN MASSACHUSETTS GEN HOSPITAL (US) 2025-05-14 EP claimed
US-20250143865-A1 METHODS AND SYSTEMS FOR PREVENTING OR REDUCING STENOSIS IN A SUBJECT RECEIVING A GRAFT MASSACHUSETTS GEN HOSPITAL (US) 2025-05-08 US claimed
US-20250121118-A1 SYSTEMS, APPARATUSES, KITS, AND METHODS FOR MODIFICATION OF TISSUE USING A PHOTO-INITIATOR AND LIGHT DURVENA INC (US) 2025-04-17 US claimed
US-12269909-B2 Polymer composition and a method of preparing a polymer resin AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2025-04-08 US claimed
WO-2025057225-A1 ENGINEERED ANTIBODIES AND USES THEREOF INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED (IN) 2025-03-20 WO claimed
EP-0910365-A1 GROWTH INHIBITION AND ERADICATION OF SOLID TUMORS USING NEUROENDOCRINE RESETTING THERAPY AND PHOTODYNAMIC THERAPY Ergo Research Corporation (US) 1999-04-28 EP claimed
EP-0885263-A1 BENZOPHENOXAZINE DYES Amersham Pharmacia Biotech UK Limited (GB) 1998-12-23 EP claimed
US-5832931-A Method for improved selectivity in photo-activation and detection of molecular diagnostic agents PHOTOGEN, INC. (US) 1998-11-10 US claimed
US-5831144-A Refrigeration compressor oil testing process and apparatus PASTORELLO JOHN (US) 1998-11-03 US claimed
WO-1997040829-A9 GROWTH INHIBITION AND ERADICATION OF SOLID TUMORS USING NEUROENDOCRINE RESETTING THERAPY AND PHOTODYNAMIC THERAPY 1998-01-22 WO claimed
WO-1997040829-A1 GROWTH INHIBITION AND ERADICATION OF SOLID TUMORS USING NEUROENDOCRINE RESETTING THERAPY AND PHOTODYNAMIC THERAPY ERGO RESEARCH CORPORATION (US) 1997-11-06 WO claimed
WO-1997029154-A1 BENZOPHENOXAZINE DYES AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) 1997-08-14 WO claimed
WO-1997026885-A1 BENZOPHENOTHIAZINE AND BENZOPORPHYRIN DYE COMBINATION PHOTODYNAMIC THERAPY OF TUMORS THE GENERAL HOSPITAL CORPORATION DOING BUSINESS AS MASSACHUSETTS GENERAL HOSPITAL (US) 1997-07-31 WO claimed
US-3997541-A Lactones of the benzazaxanthene series and dye-forming components for duplication processes BASF AKTIENGESELLSCHAFT (DT) 1976-12-14 US claimed
US-3946017-A PRESSURE SENSITIVE MATERIALS BADISCHE ANILIN- & SODA-FABRIK AKTIENGESELLSCHAFT (DT) 1976-03-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250377301-A1 STABILISED FLUOROPHORES, COMPOSITIONS, METHODS OF PREPARATION, CONJUGATES THEREOF, AND METHODS OF USE CRY1, MKI67, IK ALOX5 1864/4885DHODH 42/4885CYP1A2 950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.